Journal article
A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours
YJ Kang, S O’Haire, F Franchini, M IJzerman, J Zalcberg, F Macrae, K Canfell, J Steinberg
Scientific Reports | NATURE PORTFOLIO | Published : 2022
Open access
Abstract
Immune checkpoint inhibitors have been approved in the USA for tumours exhibiting mismatch repair deficiency (dMMR), microsatellite instability (MSI), or high tumour mutational burden (TMB), with regulatory and reimbursement applications in multiple other countries underway. As the estimated budget impacts of future reimbursements depend on the size of the potential target population, we performed a scoping review and meta-analysis of the prevalence of these pan-tumour biomarkers in different cancers. We systematically searched Medline/Embase and included studies reporting the prevalence of dMMR/MSI/high TMB in solid tumours published 01/01/2018–31/01/2021. Meta-analyses were performed separ..
View full abstractGrants
Funding Acknowledgements
This study was funded by Medical Research Future Fund (MRFF) -Preventive and Public Health Research Initiative -2019 Targeted Health System and Community Organization Research Grant Opportunity, as part of the Cancer-Patient Population Projections project (Cancer-PPP, grant number: MRF1200535) and the Predicting the population health economic impact of current and new cancer treatments project (PRIMCAT, grant number: MRF 1199701). The funder had no role in study design, data collection and analysis, decision to publish, preparation or submission of the manuscript.